---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-25-000117"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:22:02.065060+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Nurix appoints former Pfizer oncology chief Roger Dansey to board

## Summary
- Dr. Dansey appointed effective Nov 6, 2025, as Class III director and member of Clinical and Commercialization Committee.
- Former Chief Development Officer and Chief Oncology Officer at Pfizer; previously CMO and interim CEO of Seagen.
- Initial stock option grant of 50,000 shares, vesting monthly over three years; pro rata annual retainer of $50,000.
- Dansey brings experience from leading Keytruda development at Merck and Xgeva at Amgen.

## SEC filing metadata
- accession: 0001549595-25-000117
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000117/0001549595-25-000117-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000117/nrix-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-25-000117
- JSON: https://secwatch.observer/filing/0001549595-25-000117.json
- Plain text: https://secwatch.observer/filing/0001549595-25-000117.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.